Checkpoint Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Revenue	0.04	0.1	0.19	0.27	1.07	Upgrade
Revenue Growth (YoY)	-60.19%	-46.35%	-28.36%	-74.93%	-37.41%	Upgrade
Cost of Revenue	-	43.57	49.83	48.45	16.35	Upgrade
Gross Profit	0.04	-43.46	-49.63	-48.19	-15.28	Upgrade
Selling, General & Admin	20.06	8.69	8.7	8.54	7.92	Upgrade
Research & Development	36.15	-	-	-	-	Upgrade
Operating Expenses	56.22	8.69	8.7	8.54	7.92	Upgrade
Operating Income	-56.17	-52.15	-58.33	-56.72	-23.2	Upgrade
Interest & Investment Income	0.01	0.08	0.16	0.05	0.12	Upgrade
Currency Exchange Gain (Loss)	-0	-	-	-	-	Upgrade
Other Non Operating Income (Expenses)	-0.07	0.22	-4.45	-	-	Upgrade
Pretax Income	-56.24	-51.85	-62.62	-56.67	-23.08	Upgrade
Net Income	-56.24	-51.85	-62.62	-56.67	-23.08	Upgrade
Net Income to Common	-56.24	-51.85	-62.62	-56.67	-23.08	Upgrade
Shares Outstanding (Basic)	40	28	10	8	6	Upgrade
Shares Outstanding (Diluted)	40	28	10	8	6	Upgrade
Shares Change (YoY)	43.01%	169.69%	21.63%	51.48%	58.14%	Upgrade
EPS (Basic)	-1.42	-1.87	-6.09	-6.70	-4.13	Upgrade
EPS (Diluted)	-1.42	-1.87	-6.09	-6.70	-4.13	Upgrade
Gross Margin	100.00%	-	-	-	-	Upgrade
Operating Margin	-137009.76%	-50629.13%	-30381.77%	-21165.30%	-2170.35%	Upgrade
Profit Margin	-137170.73%	-50336.89%	-32616.67%	-21145.52%	-2159.12%	Upgrade
EBIT	-56.17	-52.15	-58.33	-56.72	-23.2	Upgrade

Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q